Huonslab announced on the 7th that it has confirmed that the HLB3-013 biosimilar under development is equally effective in non-clinical animal efficacy tests compared to the original Prolia. This is the result of an osteoporosis-causing model mouse at an overseas CRO institution (BioMedCore, Greece). When the original and HLB3-013 were treated equally, the effect of inhibiting osteoporosis symptoms was confirmed in various factors (average volume, density, separation, and external bone thickness of the femur). The same effect was shown at the same concentration of the test group compared to Prolia (3 mg/kg, 10 mg/kg). Prolia's mechanism of action is a drug that prevents bone destruction by binding to RANKL, an essenti